Clinical crosstalk between microRNAs and gastric cancer (Review).
Globally, there were over 1 million new gastric cancer (GC) patients in 2018 and GC has become the sixth most common cancer worldwide. GC caused 783,000 deaths worldwide in 2018, making it the third most deadly cancer type. miRNAs are short (~22 nucleotides in length) non‑coding RNA molecules, which can regulate gene expression passively at a post‑transcriptional level. There are more and more in‑depth studies on miRNAs. There are numerous conclusive evidences that there is an inseparable link between miRNAs and GC. miRNAs can affect the entire process of GC, including the oncogenesis, development, diagnosis, treatment and prognosis of GC. Although many miRNAs have been linked to GC, few can be applied to clinical practice. This review takes the clinical changes of GC as a clue and summarizes the miRNAs related to GC that have confirmed the mechanism of action in the past three years. Through in‑depth study and understanding of the mechanism of those miRNAs, we predict their possible clinical uses, and suggest some new insights to overcome GC.
['Ouyang|Jing|J|', 'Xie|Zhizhong|Z|', 'Lei|Xiaoyong|X|', 'Tang|Guotao|G|', 'Gan|Runliang|R|', 'Yang|Xiaoyan|X|']
D014408:Biomarkers, Tumor D020869:Gene Expression Profiling D015972:Gene Expression Regulation, Neoplastic D006801:Humans D035683:MicroRNAs D011379:Prognosis D013274:Stomach Neoplasms
microRNAs gastric cancer clinical applications